HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Comparison of BCG prime-DNA booster and rBCG regimens for protection against tuberculosis.

Abstract
Developing an effective adult prophylaxis vaccine is a high priority in the global control of tuberculosis (TB), because TB remains an important public health problem and the current widely used BCG vaccine provides effective protection only for children but variable protection against adult TB. BCG priming-heterologous vaccines booster and recombinant BCG technologies have been thought as two important regimens for inducing effective protection against adult TB. Obviously, defining the protective efficacy of the two regimens would benefit more rational design of the future adult TB vaccines. In this study, a recombinant BCG strain (rBCG::685A) expressing the fusion protein of ESAT-6 and Ag85A (r685A) of Mycobacterium tuberculosis was constructed successfully and the secretion of r685A protein from rBCG strain was confirmed by western blotting with anti-ESAT-6 and anti-Ag85A polyclonal antibodies, respectively. The immune responses and protective effects in rBCG::685A vaccinated C57BL/6 mice were compared with that of our previous reported BCG prime-pcD685A booster regimen. Boosting BCG with pcD685A DNA elicited higher level of r685A protein specific IFN-γ secreted by splenocytes and a more significant increase of both TNF-α and iNOS responses in the lung, thus providing better control of bacterial growth in both lung and spleen of immunized mice challenged with virulent M. tuberculosis, compared with mice vaccinated with rBCG::685A or BCG alone. Our results have implications for development of more effective adult TB vaccines for improved control of TB.
AuthorsKun Tan, Jinping Liang, Xindong Teng, Xiaochun Wang, Jingyan Zhang, Xuefeng Yuan, Xionglin Fan
JournalHuman vaccines & immunotherapeutics (Hum Vaccin Immunother) Vol. 10 Issue 2 Pg. 391-8 ( 2014) ISSN: 2164-554X [Electronic] United States
PMID24192709 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antigens, Bacterial
  • BCG Vaccine
  • Bacterial Proteins
  • Cytokines
  • ESAT-6 protein, Mycobacterium tuberculosis
  • Recombinant Fusion Proteins
  • Vaccines, DNA
  • Vaccines, Synthetic
  • Nitric Oxide Synthase Type II
  • Acyltransferases
  • antigen 85A, Mycobacterium tuberculosis
Topics
  • Acyltransferases (genetics, immunology)
  • Animals
  • Antigens, Bacterial (genetics, immunology)
  • BCG Vaccine (administration & dosage, immunology)
  • Bacterial Proteins (genetics, immunology)
  • Cytokines (metabolism)
  • Disease Models, Animal
  • Female
  • Gene Expression
  • Leukocytes, Mononuclear (immunology)
  • Lung (immunology, microbiology, pathology)
  • Mice, Inbred C57BL
  • Mycobacterium bovis (genetics, immunology)
  • Nitric Oxide Synthase Type II (metabolism)
  • Recombinant Fusion Proteins (genetics, immunology)
  • Spleen (immunology)
  • Tuberculosis (immunology, prevention & control)
  • Vaccination (methods)
  • Vaccines, DNA (administration & dosage, immunology)
  • Vaccines, Synthetic (administration & dosage, immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: